Re-evaluation of lipiodolized transarterial chemoembolization therapy for intrahepatic recurrence of hepatocellular carcinoma after curative liver resection

Abstract

Background/Purpose. While lipiodolized transarterial chemoembolization

Chemoembolization of Recurrent Hepatoma After Curative Resection: Prognostic Factors

“…The mean size of the recurrent HCC was 2.9 ± 1.7 cm and 144 (50.2%) patients had solitary recurrent HCC. During the follow-up period, the mean number of TACE sessions was 3.6 ± 2.6 (range, [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. At the time of the first TACE procedure for HCC recurrence, portal vein tumor thrombus was observed in 38 (13.2%) patients, and arterioportal shunt was identified in 59 (20.6%) patients.…”

Risk factors for postoperative recurrence of non‐B non‐C hepatocellular carcinoma

“…For patients with multiple tumors, adjuvant therapeutic approaches are also needed to prevent postoperative recurrence. In previous reports, transcatheter arterial chemotherapy [31, 32], molecular‐targeted therapies including sorafenib [33] have been identified as adjuvant therapeutic approaches. However, survival benefits have not been clearly demonstrated for adjuvant chemotherapy, transcatheter arterial chemotherapy or systemic chemotherapy.…”

A comparative study of pathological staging systems in predicting recurrent hepatocellular carcinoma after liver transplantation

“…However, with LT, chronic hepatic disease and HCC are both removed. Furthermore, there are high incidences of intrahepatic tumor recurrence after hepatic resection [11,12]. Alternatively, patients with poor liver function are not suitable for hepatic resection.…”

“…Varotti et al [15] compared the prognostic efficacy of the of the AJCC staging systems for HCC who underwent curative resection, with 173 AJCC (6th edition) stage I patients (44%), 200 stage II patients (51%), 19 stage IIIa patients (5%) and 1 stage IIIc patient. Eguchi et al [12] classified patients who underwent hepatic resection according to the AJCC 5th edition system. Their patients included 5 stage I patients (7.7%), 29 stage II patients (44.6%), 15 stage III patients (23.1%), and 8 stage IVA patients (12.3%).…”